Wallenberg Clinical Scholar Oskar Hansson has researched Alzheimer’s disease for just over twenty years. He has developed a number of methods for earlier, more accurate diagnosis. His team has been essential for the development of simple blood tests for the disease. Read more at Knut and Alice Wallenberg Foundation  

Finding a safe and simple way to diagnose Alzheimer’s disease in primary healthcare has long been a dream. This year’s recipient of the Torsten Söderberg Academy Professorship in Medicine, Oskar Hansson, Professor of Neurology at Lund University, is well on the way to making this reality. Read more at: The Royal Swedish Academy of Sciences

Is it possible that a single biomarker can detect all types of diseases related to dopamine deficiency in the brain? Yes, that’s what a research group in Lund is discovering. “We have observed that an enzyme in cerebrospinal fluid and in blood is a useful marker for identifying all types of Parkinson’s-related diseases with high

Lewy body disease is the second most common neurodegenerative disease after Alzheimer’s disease. A research group from Lund University has now shown that the disease can be detected before symptoms appear, using a spinal fluid test. The studies are published in Nature Medicine, where the researchers also demonstrate that reduced sense of smell is strongly

Three researchers at Lund University in Sweden, all with a long list of significant research credentials, have been awarded the ERC Advanced Grant worth EUR 2.5 million each to further develop and advance their research projects. One of these researchers is neuroscientist Oskar Hansson, who will use blood tests for rapid screening of drugs in

Three researchers at Lund University in Sweden, all with a long list of significant research credentials, have been awarded the ERC Advanced Grant worth EUR 2.5 million each to further develop and advance their research projects. This concerns research on a fundamentally changed food system, chaperone proteins’ function in neurodegenerative diseases, and blood tests for

A new study have identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and also another blood test that is optimal for detecting relevant treatment effects. These findings will speed up the development of new therapies that can slow down the disease progression. Read more at: Multipark, Lund University

The brain’s big-eating immune cells can slow down the progression of Alzheimer’s disease. This is shown by a study that is now published in Nature Aging. The brain’s own immune cells are called microglia and are found in the central nervous system. They are big eaters that kill viruses, damaged cells and infectious agents they

A large study led by Lund University in Sweden has shown that people with Alzheimer’s disease can now be identified before they experience any symptoms. It is now also possible to predict who will deteriorate within the next few years. The study is published in Nature Medicine, and is very timely in light of the

MultiPark’s scientists conduct world-leading research in biomarkers for Alzheimer’s disease, led by Professor Oskar Hansson at the memory clinic at Skåne University Hospital. He recently met with Bill Gates to discuss the future possibilities in this field. Read more at: MultiPark, Lund University

Alzheimer’s Association recently released recommendations about using blood-based biomarkers to detect Alzheimer’s disease. The recommendations are based on research conducted by Oskar Hansson, one of MultiPark’s research group leaders. “Blood-based biomarkers for Alzheimer’s are already improving the design of clinical trials, and they are very likely to revolutionize the diagnosis of Alzheimer’s in the future,”

With the support of an EU grant of 1.9 million euros, Alzheimer’s researcher Oskar Hansson will lead and coordinate a research collaboration between Sweden, Spain, France, Germany and Denmark. The goal is to create conditions for early and correct diagnosis of Alzheimer’s disease. This is to improve the treatment and care of the patients and

Oskar Hansson belönas för sin forskning som bland annat visat på att nya blodmarkörer kan avsevärt förbättra diagnostiken av Alzheimers sjukdom. På sikt kommer detta hjälpa patienter runt världen med att få en riktig diagnos och därmed korrekt behandling och vård. Läs mer här

She’s a chemist. He’s a medic. Together, they stand behind some of the recent major research breakthroughs on Alzheimer’s disease. Sara Linse and Oskar Hansson is now laying the foundation for future drugs and diagnostic methods. It is such an unusual morning in late November when the sun does not have to fight against the